Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vanda Pharmaceuticals (VNDA) Research & Development (2016 - 2025)

Vanda Pharmaceuticals' Research & Development history spans 16 years, with the latest figure at $29.0 million for Q4 2025.

  • For Q4 2025, Research & Development rose 46.2% year-over-year to $29.0 million; the TTM value through Dec 2025 reached $109.3 million, up 46.81%, while the annual FY2025 figure was $109.3 million, 46.81% up from the prior year.
  • Research & Development for Q4 2025 was $29.0 million at Vanda Pharmaceuticals, up from $22.6 million in the prior quarter.
  • Across five years, Research & Development topped out at $35.7 million in Q1 2025 and bottomed at $16.1 million in Q1 2021.
  • The 5-year median for Research & Development is $20.0 million (2021), against an average of $21.1 million.
  • The largest annual shift saw Research & Development surged 5423.14% in 2021 before it tumbled 33.22% in 2023.
  • A 5-year view of Research & Development shows it stood at $19.3 million in 2021, then fell by 4.54% to $18.5 million in 2022, then soared by 31.89% to $24.3 million in 2023, then fell by 18.48% to $19.8 million in 2024, then soared by 46.2% to $29.0 million in 2025.
  • Per Business Quant, the three most recent readings for VNDA's Research & Development are $29.0 million (Q4 2025), $22.6 million (Q3 2025), and $22.0 million (Q2 2025).